



Published in final edited form as:

Infect Control Hosp Epidemiol. 2024 May ; 45(5): 590–598. doi:10.1017/ice.2023.262.

Potential underreporting of treated patients using a *Clostridioides difficile* testing algorithm that screens with a nucleic acid amplification test

Alice Y. Guh, MD, MPH¹, Scott Fridkin, MD^{2,3}, Dana Goodenough, MPH^{2,3,4}, Lisa G. Winston, MD⁵, Helen Johnston, MPH⁶, Elizabeth Basiliere, AAS⁶, Danyel Olson, MS, MPH⁷, Christopher D. Wilson, MD, MPH⁸, Jasmine J. Watkins, MS, MPH⁸, Lauren Korhonen, MSPH¹, Dale N. Gerding, MD⁹

¹Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia

²Emory University School of Medicine, Atlanta, Georgia

³Georgia Emerging Infections Program, Decatur, Georgia

⁴Atlanta Veterans' Affairs Medical Center, Decatur, Georgia

⁵University of California, San Francisco, School of Medicine, San Francisco, California

⁶Colorado Department of Public Health and Environment, Denver, Colorado

⁷Connecticut Emerging Infections Program, Yale School of Public Health, New Haven, Connecticut

⁸Tennessee Department of Health, Nashville, Tennessee

⁹Edward Hines, Jr., Veterans' Affairs Hospital, Hines, Illinois

Abstract

Objective: Patients tested for *Clostridioides difficile* infection (CDI) using a 2-step algorithm with a nucleic acid amplification test (NAAT) followed by toxin assay are not reported to the National Healthcare Safety Network as a laboratory-identified CDI event if they are NAAT positive (+)/toxin negative (–). We compared NAAT+/toxin– and NAAT+/toxin+ patients and identified factors associated with CDI treatment among NAAT+/toxin– patients.

To the extent this is a work of the US Government, it is not subject to copyright protection within the United States. To the extent this work is subject to copyright outside of the United States, such copyright shall be assigned to The Society for Healthcare Epidemiology of America and licensed to the Publisher. Outside of the United States, the US Government retains a paid up, nonexclusive, irrevocable worldwide license to reproduce, prepare derivative works, distribute copies to the public and display publicly the Contribution, and to permit others to do so. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

Corresponding author: Alice Y. Guh; ggt4@cdc.gov.

Supplementary material. To view supplementary material for this article, please visit <https://doi.org/10.1017/ice.2023.262>

Competing interests. D.N.G. is a consultant for Destiny Pharma and Sebela Pharmaceuticals and holds technology for the treatment of CDI with nontoxicogenic *C. difficile* licensed to Destiny Pharma. All other authors have no known conflicts of interest.

Design: Retrospective observational study.

Setting: The study was conducted across 36 laboratories at 5 Emerging Infections Program sites.

Patients: We defined a CDI case as a positive test detected by this 2-step algorithm during 2018–2020 in a patient aged ≥ 1 year with no positive test in the previous 8 weeks.

Methods: We used multivariable logistic regression to compare CDI-related complications and recurrence between NAAT+/toxin– and NAAT+/toxin+ cases. We used a mixed-effects logistic model to identify factors associated with treatment in NAAT+/toxin– cases.

Results: Of 1,801 cases, 1,252 were NAAT+/toxin–, and 549 were NAAT+/toxin+. CDI treatment was given to 866 (71.5%) of 1,212 NAAT+/toxin– cases versus 510 (95.9%) of 532 NAAT+/toxin+ cases ($P < .0001$). NAAT+/toxin– status was protective for recurrence (adjusted odds ratio [aOR], 0.65; 95% CI, 0.55–0.77) but not CDI-related complications (aOR, 1.05; 95% CI, 0.87–1.28). Among NAAT+/toxin– cases, white blood cell count $\geq 15,000/\mu\text{L}$ (aOR, 1.87; 95% CI, 1.28–2.74), ≥ 3 unformed stools for ≥ 1 day (aOR, 1.90; 95% CI, 1.40–2.59), and diagnosis by a laboratory that provided no or neutral interpretive comments (aOR, 3.23; 95% CI, 2.23–4.68) were predictors of CDI treatment.

Conclusion: Use of this 2-step algorithm likely results in underreporting of some NAAT+/toxin– cases with clinically relevant CDI. Disease severity and laboratory interpretive comments influence treatment decisions for NAAT+/toxin– cases.

Laboratory methods for diagnosing *Clostridioides difficile* infection (CDI), a toxin-mediated disease, have evolved in the United States over the past decade. Nucleic acid amplification tests (NAATs), which first became available in the late 2000s, are highly sensitive for toxigenic *C. difficile* since they detect the toxin gene but not the actual toxin.¹ Early reports of missed CDI diagnosis due to the poor sensitivity of toxin enzyme immunoassays (EIAs) led to increased use of NAATs.^{2–5} From 2011 to 2017, across multiple US sites, the percentage of incident CDI episodes diagnosed by NAAT alone or as the last test of a multistep algorithm increased from 55% to 83%.⁶ However, as facilities switched from toxin EIA to NAAT, CDI incidence rates increased by 43%–67%.⁷ In addition, evidence started emerging that use of NAAT can potentially lead to an overdiagnosis of CDI (ie, colonization instead of active infection), particularly when used indiscriminately without considering other causes of diarrhea.^{8–10} Consequently, a growing number of US facilities have switched to a 2-step algorithm that has been widely adopted in Europe, which consists of an initial screening with NAAT, and if positive, reflexes to a toxin EIA.^{11,12}

Almost all US hospitals are required to report CDI as a laboratory-identified (LabID) event to the National Healthcare Safety Network (NHSN), the nation's largest surveillance system for healthcare-associated infections.¹³ In 2018, the NHSN changed its reporting protocol to allow facilities that use a multistep algorithm to use only the result of the last test for reporting a CDI LabID event.¹⁴ Thus, facilities using the 2-step algorithm would not report an NAAT positive (+)/toxin negative (–) result (ie, NAAT-positive result followed by a toxin EIA-negative result) to the NHSN, which has led to decreased CDI rates in some facilities.¹⁵ However, recent studies indicate that some patients with an NAAT+/toxin– result are treated for CDI,^{16–23} suggesting that a portion of unreported NAAT+/toxin– results are considered

active infection. To explore this discrepancy, we conducted a multisite analysis of patients tested by this 2-step algorithm to determine whether NAAT+/toxin– patients had similar characteristics and were as likely to receive CDI treatment as NAAT+/toxin+ patients. We also sought to identify factors associated with CDI treatment among NAAT+/toxin– patients.

Methods

CDI surveillance and case definition

The CDC Emerging Infections Program (EIP) conducts active laboratory- and population-based CDI surveillance in 10 US sites.²⁴ The surveillance protocol underwent ethical review by CDC and EIP sites and either was deemed nonresearch or received an institutional review board approval with a waiver of informed consent.

Laboratories serving the surveillance areas reported all positive *C. difficile* tests to EIP site staff, including positive tests conducted as part of an algorithm in which the final test is negative. As of 2020, 5 EIP sites (ie, California, Colorado, Connecticut, Georgia, and Tennessee) had laboratories that used this 2-step algorithm for CDI diagnosis. One of the EIP sites had laboratories that only performed the 2-step algorithm in hospitalized patients; laboratories in the other 4 EIP sites had no known testing restrictions. For this analysis, an incident CDI case was defined as a positive *C. difficile* molecular or toxin assay detected during 2018–2020 by the 2-step algorithm in a person aged ≥1 year who did not have a positive test in the prior 8 weeks.

Data collection

An initial limited chart review was performed on all cases in 4 EIP sites and on a random sample of cases in 1 EIP site (Fig. 1), as previously described.²⁵ Based on this review, cases were classified as (1) community-onset if the *C. difficile*–positive stool was collected as an outpatient or within 3 days of hospital admission; (2) hospital-onset if the positive stool was collected >3 days after hospital admission; or (3) long-term care facility (LTCF) onset if the positive stool was collected in an LTCF or from an LTCF resident.

In accordance with the EIP surveillance protocol, all community-onset cases and a random 10%–20% sample of hospital-onset and LTCF-onset cases underwent a subsequent full chart review to collect underlying comorbidities, relevant healthcare and medication exposures, clinical course, and CDI treatment (Fig. 1). Community-onset cases were further classified as community associated if there was no documentation of an overnight stay in a healthcare facility in the preceding 12 weeks. All other community-onset cases were considered healthcare facility associated, and, along with hospital-onset and LTCF-onset cases, were classified as healthcare-associated CDI cases.

Participating laboratories were surveyed annually regarding their *C. difficile* testing method. Laboratories that utilized the 2-step algorithm were asked to share the interpretive comments that they use when reporting out an NAAT+/toxin– result. This information was used to classify laboratories into 2 groups by 3 investigators (A.G., S.F., and D.G.): (1) those that provide no accompanying comments or use neutral wording when reporting an NAAT+/-

toxin– result (eg, the result could represent colonization or active infection) or (2) those indicating that an NAAT+/toxin– result likely represents *C. difficile* colonization.

Statistical analysis

Only cases with a full chart review were included in the analysis. Cases were considered as treated for CDI if they were prescribed an appropriate antibiotic treatment according to guidelines²⁶ for ≥ 7 days or were treated until discharge (and had received ≥ 2 days of treatment), colectomy, or death. Cases who received fecal microbiota transplantation (FMT) were also considered to have been treated for CDI. Comparisons of NAAT+/toxin– versus NAAT+/toxin+ cases and treated versus untreated NAAT+/toxin– cases were described using the χ^2 and Fisher exact tests (where applicable) for categorical variables and the Wilcoxon rank-sum test for continuous variables. Multiple imputation was performed for the race variable (7.5% of cases were missing) and ethnicity variable (14.2% of cases were missing) using the fully conditional specification method based on age, sex, epidemiologic classification, EIP site, and year.

Separate multivariable logistic regression models were used to compare CDI-related complications (defined as toxic megacolon, ileus, colectomy, or intensive-care unit stay) and CDI recurrence (defined as a *C. difficile*-positive molecular or toxin assay 2–8 weeks following the initial positive test) between NAAT+/toxin– and NAAT+/toxin+ cases. Each model was adjusted for age, sex, race, epidemiologic classification (healthcare-associated versus community-associated CDI), Charlson comorbidity index, and receipt of vancomycin or fidaxomicin within 3 days before or after stool collection. For the outcome of recurrence, we also adjusted for history of CDI in the prior 6 months.

To identify factors associated with CDI treatment among NAAT+/toxin– cases, we used a mixed-effects logistic model adjusting for site clustering (with EIP site as random effect). NAAT+/toxin– cases with missing treatment data or unknown duration of treatment were excluded from the model. The following variables were determined a priori to be potentially associated with treatment and were included in the initial model: age, sex, race/ethnicity, selected comorbidities and healthcare and medication exposures, prior history of CDI, ≥ 3 unformed stools for ≥ 1 day, hospital-onset status, hospitalization, white blood cell (WBC) count ≥ 15,000/ μ L, and category of laboratory comments regarding an NAAT+/toxin– result. Variables with a *P* value < .10 in the initial model were included in the final model.

Adjusted odds ratios (aOR) and 95% confidence intervals (CI) were calculated for each of the models. A 2-tailed *P* value < .05 was considered statistically significant. SAS version 9.4 statistical software (SAS Institute, Cary, NC) was used for all analyses.

Results

Risk factors and clinical characteristics

Of 1,801 cases with a full chart review reported from 36 laboratories, 1,252 (69.5%) were NAAT+/toxin– and 549 (30.5%) were NAAT+/toxin+. The CDI diagnostic assays used by participating laboratories are described in the Supplementary Materials and Supplementary Table S1 (online). A lower percentage of NAAT+/toxin– cases than NAAT+/toxin+ cases

were female (57.0% vs 63.9%; $P = 0.006$), non-Hispanic White (48.6% vs 57.9%; $P = .003$), and healthcare associated (37.2% vs 52.1%; $P < .0001$) (Table 1). Median age was lower among NAAT+/toxin– cases than among NAAT+/toxin+ cases (61 vs 67 years; $P < .0001$). NAAT+/toxin– cases were also less likely than NAAT+/toxin+ cases to have been hospitalized (34.1% vs 47.5%; $P < .0001$), to have stayed in an LTCF (3.3% vs 9.8%; $P < .0001$), to have had surgery (9.0% vs 17.5%; $P < .0001$), or to have received antibiotics (63.0% vs 81.2%; $P < .0001$) in the 12 weeks preceding their CDI diagnosis.

Documentation of any diarrhea (1 unformed stool) occurred less frequently among NAAT+/toxin– than NAAT+/toxin+ cases: 1,084 (93.8%) of 1,156 versus 506 (97.5%) of 519 ($P = .001$). However, both groups had a similar proportion with 3 unformed stools for 1 day (49.9% versus 54.1%; $P = .11$). A lower percentage of NAAT+/toxin– cases than NAAT+/toxin+ cases had WBC count $> 15,000/\mu\text{L}$ (23.9% vs 40.8%; $P < .0001$), serum albumin < 2.5 g/dL (25.2% vs 31.1%; $P = .02$), pseudomembranous colitis (14.3% vs 40.0%; $P = .009$), and CDI recurrence (7.8% vs 16.6%; $P < .0001$) (Table 1).

In multivariable analysis, NAAT+/toxin– status was protective for CDI recurrence (aOR, 0.65; 95% CI, 0.55–0.77) but not for CDI-related complications (aOR, 1.05; 95% CI, 0.87–1.28) (Table 2).

CDI treatment

CDI treatment was prescribed to 866 (71.5%) of 1,212 NAAT+/toxin– versus 510 (95.9%) of 532 NAAT+/toxin+ cases ($P < .0001$) (Table 3). Both NAAT+/toxin– and NAAT+/toxin+ cases had the same median duration of treatment of 12 days (IQR, 10–15). A similar proportion of NAAT+/toxin– and NAAT+/toxin+ cases with CDI-related complications received treatment within 48 hours of CDI diagnosis (93.7% vs 100.0%; $P = .08$). Overall, NAAT+/toxin– cases were less likely than NAAT+/toxin+ cases to have received fidaxomicin (2.7% vs 7.1%; $P < .0001$). Documentation of FMT was rare among both NAAT+/toxin– and NAAT+/toxin+ cases (0.8%). Similar results were seen when stratified by hospital-onset status (Table 3).

The percentage of treated NAAT+/toxin– cases per EIP site ranged from 40% to 79%. Laboratories located in the same EIP site often used similar language for reporting an NAAT+/toxin– result (Table S2). As of 2020, of the 36 laboratories, 20 (55.6%) located in 5 EIP sites provided comments indicating that an NAAT+/toxin– result likely represented colonization, and 16 (44.4%) located in four EIP sites provided either no comments ($n = 3$) or neutral comments ($n = 13$). NAAT+/toxin– cases reported by the former language were less likely to have received CDI treatment compared to NAAT+/toxin– cases reported by the latter language: 358 (60.7%) of 590 versus 508 (81.7%) of 622 ($P < .0001$). Testing for other enteric pathogens was performed for 611 (49%) of the NAAT+/toxin– cases; of these, 57 (9.3%) tested positive for another enteric pathogen, of whom 36 (63.2%) still received CDI treatment. A comparison of treated and untreated NAAT+/toxin– cases is shown in Table 4.

The initial multivariable model to identify factors associated with CDI treatment in NAAT+/toxin– cases is shown in Supplementary Table S3 (online). In the final multivariable analysis, WBC $> 15,000/\mu\text{L}$ (aOR, 1.87; 95% CI, 1.28–2.74), 3 unformed stools for 1 day

(aOR, 1.90; 95% CI, 1.40–2.59), and diagnosis by a laboratory that provided no or neutral comments (aOR, 3.23; 95% CI, 2.23–4.68) were significantly associated with receiving CDI treatment among NAAT+/toxin– cases (Table 5). Non-Hispanic, race other than White, compared to non-Hispanic White race (aOR, 0.67; 95% CI, 0.47–0.94), history of CDI in the prior 6 months (aOR, 0.47; 95% CI, 0.26–0.87), and being hospitalized (aOR, 0.54; 95% CI, 0.35–0.86) were associated with no CDI treatment among NAAT+/toxin– cases.

Discussion

In our large, multisite analysis, NAAT+/toxin– cases were less likely to have traditional CDI risk factors and recurrence but were as likely to have CDI-related complications as NAAT+/toxin+ cases. Notably, although almost all NAAT+/toxin+ cases were treated for CDI, the number of NAAT+/toxin– cases who received CDI treatment was 1.7 times that of NAAT+/toxin+ cases, given the larger number of NAAT+/toxin– cases. A subset of these treated NAAT+/toxin– cases were hospitalized but would not have been reported to the NHSN as a CDI LabID event, indicating that the use of the 2-step algorithm may result in underreporting of clinically relevant CDI.

NAAT+/toxin– patients are more likely to be colonized with *C. difficile*, as indicated by a smaller proportion with traditional CDI risk factors (eg, older age, prior healthcare exposures). However, the findings of pseudomembranous colitis and recurrent CDI among our NAAT+/toxin– cases, albeit at a lower rate than in the NAAT+/toxin+ cases, indicate that a subgroup likely has CDI. Despite having milder disease, NAAT+/toxin– cases had a similar rate of CDI-related complications as NAAT+/toxin+ cases even after adjusting for potential confounders, which is consistent with a previous analysis.²⁷ Furthermore, 2 of the NAAT+/toxin– cases required colectomy. Several studies have described similar clinical manifestations and outcomes, including fulminant colitis and colectomy, among a small subset of NAAT+/toxin– patients,^{23,27-29} and as many as 43%–73% of NAATA+/toxin– patients may have probable or possible CDI based on clinical reviews.^{18,22,29}

In response to concerns that the current NHSN CDI LabID event definition does not distinguish between colonization and infection and might influence the choice of testing strategy, the NHSN is updating its CDI surveillance definition to include any positive *C. difficile* test and receipt of CDI treatment.³⁰ The updated CDI measure, known as healthcare-facility–onset, antibiotic-treated CDI (HT-CDI), has completed validation, and if widely implemented, could improve the reporting of clinically relevant NAAT+/toxin– cases. However, this is predicated on the assumption that clinicians can determine the appropriate NAAT+/toxin– patient to treat, which remains a conundrum.³¹ For example, we found 28.5% of NAAT+/toxin– cases were not treated for CDI, and 8% of the untreated NAAT+/toxin– cases had a subsequent recurrence as defined in this study. Although this finding is similar to the recurrence rate of the treated NAAT+/toxin– cases (Table 2), it suggests that some of the untreated NAAT+/toxin– cases might have had active infection at the time of their initial presentation and would probably have benefited from treatment. In contrast, 71.5% of NAAT+/toxin– cases received CDI treatment, and it is unclear what proportion of these cases might represent overtreatment. Studies that assessed outcomes of untreated NAAT+/toxin– patients have mostly reported no increase in adverse outcomes

at 30 days or 8 weeks,^{8,20,29} indicating that most may not need CDI treatment. Although the results of these studies are largely reassuring, a small number of untreated NAAT+/toxin- patients had clinical worsening requiring initiation of treatment and CDI-related ICU admission.^{23,29}

Although treatment decisions should be based on individual patient assessment, they are likely influenced by how the test results are presented, such as whether the NAAT+ and toxin- results are reported sequentially or simultaneously and whether they are accompanied by any interpretive comments.³¹ In fact, the absence of any comments or the use of neutral wording to report the NAAT+/toxin- result (eg, the result could represent either colonization or active infection) was significantly associated with receiving CDI treatment. Conversely, NAAT+/toxin- cases were significantly less likely to be treated if there was wording indicating that the patient may be colonized. This finding is consistent with a study that found that switching from NAAT testing to the 2-step algorithm and reporting an NAAT+/toxin- result as “likely colonized” was associated with a decreased likelihood of CDI treatment.¹⁷

Not surprisingly, having leukocytosis and 3 unformed stools for 1 day were significant predictors of CDI treatment in NAAT+/toxin- cases. In contrast, having CDI in the prior 6 months was associated with less CDI treatment, which was unexpected, given that risk of CDI increases after a previous episode. It is not known, however, what proportion of the prior CDI episodes were not known to the clinician or were also NAAT+/toxin- and may have been considered colonization. Interestingly, being hospitalized was also protective against treatment. This finding might reflect greater access to antimicrobial stewardship experts and other specialists who may have a higher threshold for treating NAAT+/toxin- patients. Similarly, in another study, infectious diseases consultations were associated with not prescribing CDI treatment to NAAT+/toxin- patients.²³

Our analysis had several limitations. Because only a sample of hospital-onset cases underwent full chart review and could be included in our analysis, our data might not be representative of hospital-onset cases, which are targeted by pay-for-performance programs. However, sampling was performed randomly to minimize bias. Although this large, multisite analysis was conducted across diverse geographical areas, our findings might not be representative of all facilities reporting to the NHSN. Relevant exposures and treatment data could have been underestimated if there was incomplete documentation in patient charts or if parts of the chart were unavailable for review. In addition, relevant imaging studies and laboratory work were not performed for every patient, especially outpatients, which may have limited our ability to assess CDI-related complications and disease severity. We did not systematically capture positive *C. difficile* tests of patients who sought care outside the surveillance catchment areas, which could have underestimated prior and recurrent CDI rates. Recurrence could have also been underestimated because it relies on clinical practice of test ordering, and intensity of testing diarrheal stools has been shown to vary between institutions.³² We also did not collect information on whether there were dedicated antimicrobial stewardship staff reviewing every NAAT+/toxin- result, which could have influenced treatment decisions. Lastly, we only evaluated the use of NAAT as a screening test, and we did not assess the potential use of glutamate dehydrogenase (GDH)-based

screening. However, our findings are similar to those of a prior analysis that evaluated an algorithm utilizing GDH/toxin EIA with reflex to NAAT for discrepant results.²⁷

In conclusion, the 2-step algorithm can result in substantial underreporting to the NHSN of treated NAAT+/toxin- patients, some of whom may have active infection. The interpretive comments used for presenting an NAAT+/toxin- result can be helpful in reducing unnecessary CDI treatment, but if the language biases the clinician to view every NAAT+/toxin- patient as colonized, the comments could prevent CDI treatment in a subset of patients who might benefit. Furthermore, although the new NHSN CDI metric is intended to better capture clinically relevant CDI, it could potentially tip the scales toward undertreatment of NAAT+/toxin- patients in facilities that are attempting to lower their reported CDI rates. Thus, it remains critical that treatment decisions should be driven by patient's clinical presentation and risk factors rather than by the type of test or metric used. Further research is needed to determine which NAAT+/toxin- patients are likely to benefit from CDI treatment. This research should build upon the efforts of a small number of observational studies that have attempted to identify predictors of CDI-related complications to help inform treatment decisions,^{23,28} as well as advancing the research in CDI diagnostic assays to accurately distinguish true infection from colonization.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments.

We thank Rongxia Li from the Centers for Disease Control and Prevention for her statistical support. We also thank the following individuals for their contribution to the Emerging Infections Program CDI surveillance activity: Miranda Smith from the Tennessee Department of Health and Erin Parker from the California Emerging Infections Program.

Financial support.

This work was supported by the National Center for Emerging and Zoonotic Infectious Diseases at the US Centers for Disease Control and Prevention through the Emerging Infections Program Cooperative Agreement. The findings and conclusions in this manuscript are those of the authors and do not necessarily represent the official position of the US Centers for Disease Control and Prevention.

References

1. Burnham CA, Carroll KC. Diagnosis of *Clostridium difficile* infection: an ongoing conundrum for clinicians and for clinical laboratories. Clin Microbiol Rev 2013;26:604–630. [PubMed: 23824374]
2. Dallal RM, Harbrecht BG, Boujoukas AJ, et al. Fulminant *Clostridium difficile*: an underappreciated and increasing cause of death and complications. Ann Surg 2002;235:363–372. [PubMed: 11882758]
3. Johal SS, Hammond J, Solomon K, James PD, Mahida YR. *Clostridium difficile* associated diarrhoea in hospitalised patients: onset in the community and hospital and role of flexible sigmoidoscopy. Gut 2004;53:673–677. [PubMed: 15082585]
4. Humphries MR, Uslan DZ, Rubin Z. Performance of *Clostridium difficile* toxin enzyme immunoassay and nucleic acid amplification tests stratified by patient disease severity. J Clin Microbiol 2013;51:869–873. [PubMed: 23269736]
5. Cohen HS, Gerding ND, Johnson S, et al. Clinical practice guidelines for *Clostridium difficile* infection in adults: 2010 update by the Infectious Diseases Society of America (IDSA) and Society

- for Healthcare Epidemiology of America (SHEA). *Infect Control Hosp Epidemiol* 2010;31:431–455. [PubMed: 20307191]
6. Guh AY, Mu Y, Winston LG, Johnston H et al. Trends in US burden of *Clostridioides difficile* infection and outcomes. *N Engl J Med* 2020;382:1320–1330. [PubMed: 32242357]
 7. Gould CV, Edwards JR, Cohen J, et al. Effect of nucleic acid amplification testing on population-based incidence rates of *Clostridium difficile* infection. *Clin Infect Dis* 2013;57:1304–1307. [PubMed: 23899677]
 8. Polage CR, Gyorke CE, Kennedy MA, et al. Overdiagnosis of *Clostridium difficile* infection in the molecular test era. *JAMA Intern Med* 2015;175:1792–1801. [PubMed: 26348734]
 9. Planche TD, Davies KA, Coen PG, et al. Differences in outcome according to *Clostridium difficile* testing method: a prospective multicentre diagnostic validation study of *C. difficile* infection. *Lancet Infect Dis* 2013;13:936–945. [PubMed: 24007915]
 10. Baker I, Leeming JP, Reynolds R, et al. Clinical relevance of a positive molecular test in the diagnosis of *Clostridium difficile* infection. *J Hosp Infect* 2013;84:311–315. [PubMed: 23831282]
 11. Crobach MJT, Planche T, Eckert C, et al. European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for *Clostridium difficile* infection. *Clin Microbiol Infect* 2016;22:S63–81. [PubMed: 27460910]
 12. Wilcox MH. Overcoming barriers to effective recognition and diagnosis of *Clostridium difficile* infection. *Clin Microbiol Infect* 2012;18:13–20. [PubMed: 23121550]
 13. National Healthcare Safety Network (NHSN). Centers for Disease Control and Prevention website. <https://www.cdc.gov/nhsn/index.html>. Accessed April 13, 2023.
 14. National Healthcare Safety Network. Multidrug-resistant organism & *Clostridioides difficile* infection (MDRO/CDI) module. Centers for Disease Control and Prevention website. https://www.cdc.gov/nhsn/pdfs/pscmanual/12pscmdro_cdadcurrent.pdf. Accessed April 13, 2023.
 15. McCauley BP, Evans ME, Simbartl LA, Gamage SD, Kralovic SM, Roselle GA. Effect of testing methods on incidence of *Clostridioides difficile* infection rates in Veterans' Affairs medical centers. *Infect Control Hosp Epidemiol* 2021;42:461–463. [PubMed: 33185177]
 16. Evans ME, McCauley BP, Simbartl LA. Association between *Clostridioides difficile* infection testing results and decision to treat. *Infect Control Hosp Epidemiol* 2022;43:1940–1941. [PubMed: 34325761]
 17. Dbeibo L, Lucky CW, Fadel WF, et al. Two-step algorithm-based *Clostridioides difficile* testing as a tool for antibiotic stewardship. *Clin Microbiol Infect* 2023;29:798.e1798.e4.
 18. Hecker MT, Son AH, Zuccaro P, Conti J, Donskey CJ. Real-world evaluation of a two-step testing algorithm for *Clostridioides difficile* infection. *Infect Control Hosp Epidemiol* 2023;44:1494–1496. [PubMed: 36750229]
 19. Hitchcock MM, Holubar M, Hogan CA, Tompkins LS, Banaei N. Dual reporting of *Clostridioides difficile* PCR and predicted toxin result based on PCR cycle threshold reduces treatment of toxin-negative patients without increases in adverse outcomes. *J Clin Microbiol* 2019;57:e01288–19. [PubMed: 31511334]
 20. Hogan CA, Hitchcock MM, Frost S, et al. Clinical outcomes of treated and untreated *C. difficile* PCR-positive/toxin-negative adult hospitalized patients: a quasi-experimental noninferiority study. *J Clin Microbiol* 2022;60:e0218721. [PubMed: 35611653]
 21. Lenggenhager L, Zanella M-C, Poncet A, et al. Discordant *Clostridioides difficile* diagnostic assay and treatment practice: a cross-sectional study in a tertiary-care hospital, Geneva, Switzerland. *BMJ Open* 2020;10:e036342.
 22. Lowe CF, Shakeraneh S, Lee C, Sharma A, Leung V. Optimizing the interpretation of *Clostridioides difficile* two-step diagnostic algorithm results through antimicrobial stewardship. *Antimicrob Steward Health Epidemiol* 2022;2:e201.
 23. Miller R, Morillas JA, Brizendine KD, Fraser TG. 2020. Predictors of *Clostridioides difficile* infection-related complications and treatment patterns among nucleic acid amplification test-positive/toxin enzyme immunoassay-negative patients. *J Clin Microbiol* 58:e01764–19. [PubMed: 31896665]

24. Healthcare-associated infections–community interface. *Clostridioides difficile* infection (CDI) tracking. Centers for Disease Control and Prevention website. <https://www.cdc.gov/hai/eip/cdiff-tracking.html>. Accessed April 13, 2023.
25. Lessa FC, Mu Y, Winston LG et al. Determinants of *Clostridium difficile* infection incidence across diverse United States geographic locations. *Open Forum Infect Dis* 2014;1:ofu048. [PubMed: 25734120]
26. McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for *Clostridium difficile* infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). *Clin Infect Dis* 2018; 66:e1–e48. [PubMed: 29462280]
27. Guh AY, Hatfield KM, Winston LG et al. Toxin enzyme immunoassays detect *Clostridioides difficile* infection with greater severity and higher recurrence rates. *Clin Infect Dis* 2019;69:1667–1674. [PubMed: 30615074]
28. Origüen J, Corbella L, Orellana MÁ, et al. Comparison of the clinical course of *Clostridium difficile* infection in glutamate dehydrogenase-positive toxin–negative patients diagnosed by PCR to those with a positive toxin test. *Clin Microbiol Infect* 2018;24:414–21. [PubMed: 28811244]
29. Zou J, Leung V, Champagne S, et al. Clinical heterogeneity of patients with stool samples testing PCR+/Tox– from a two-step *Clostridium difficile* diagnostic algorithm. *Eur J Clin Microbiol Infect Dis* 2018;37:2355–2359. [PubMed: 30238342]
30. Kociolek LK, Gerding DN, Carrico R, et al. Strategies to prevent *Clostridioides difficile* infections in acute-care hospitals: 2022 Update. *Infect Control Hosp Epidemiol* 2023;44:527–549. [PubMed: 37042243]
31. Gerding DN. To treat or not to treat: *Clostridioides difficile* infection (CDI) guidelines, diagnostic algorithms, and CDI reporting. *Infect Control Hosp Epidemiol* 2023;44:1369–1370. [PubMed: 37198945]
32. Fridkin SK, Onwubiko UN, Dube W, et al. Determinates of *Clostridioides difficile* infection (CDI) testing practices among inpatients with diarrhea at selected acute-care hospitals in Rochester, New York, and Atlanta, Georgia, 2020–2021. *Infect Control Hosp Epidemiol* 2022;14:1–8.




Figure 1.

Flow diagram depicting the selection of reported cases for chart review and inclusion in the analysis. Note. EIP, Emerging Infections Program; NAAT, nucleic acid amplification test.

^aHealthcare facility-onset cases included hospital-onset and long-term care facility onset cases. ^bThe distribution of sampled and non-sampled healthcare facility-onset cases did not differ by sex (52.1% vs 48.9% male; $P = .51$) or age group (61.5% vs 58.1% were aged ≥ 65 years; $P = .66$), but there were fewer NAAT+/toxin- cases in the sampled group than in the nonsampled group (56.4% vs 69.0%; $P = .008$).

Comparison of Risk Factors and Clinical Characteristics Between NAAT+/toxin- and NAAT+/toxin+ *Clostridioides difficile* Infection Cases

Table 1.

Variable	Overall (N = 1,801), No. (%) ^a	NAAT+/Toxin- (n = 1,252), No. (%) ^a	NAAT+/Toxin+ (n = 549), No. (%) ^a	P Value
EIP site				.04
California	145 (8.1)	105 (8.4)	40 (7.3)	
Colorado	270 (15.0)	197 (15.7)	73 (13.3)	
Connecticut	110 (6.1)	63 (5.0)	47 (8.6)	
Georgia	799 (44.4)	551 (44.0)	248 (45.2)	
Tennessee	477 (26.5)	336 (26.8)	141 (25.7)	
Demographic				
Sex, female	1,065 (59.1)	714 (57.0)	351 (63.9)	.006
Race/ethnicity				.003
Hispanic, any race	104 (5.8)	77 (6.2)	27 (4.9)	
Non-Hispanic, White race	927 (51.5)	609 (48.6)	318 (57.9)	
Non-Hispanic, other race	493 (27.4)	368 (29.4)	125 (22.8)	
Unknown	277 (15.4)	198 (15.8)	79 (14.4)	
Age, median y (IQR)	63 (45–74)	61 (43–72)	67 (51–78)	<.0001
Epidemiologic classification				<.0001
Community associated	1,049 (58.3)	786 (62.8)	263 (47.9)	
Healthcare associated	752 (41.8)	466 (37.2)	286 (52.1)	
Community-onset healthcare facility-associated	635 (35.3)	400 (32.0)	235 (42.8)	
Hospital onset	95 (5.3)	58 (4.6)	37 (6.7)	
Long-term care facility onset	22 (1.2)	8 (0.6)	14 (2.6)	
Charlson comorbidity index				.42
0	592/1,797 (32.9)	410/1,248 (32.9)	182 (33.2)	
1	292/1,797 (16.3)	212/1,248 (17.0)	80 (14.6)	
2	913/1,797 (50.8)	626/1,248 (50.2)	287 (52.3)	
Prior healthcare exposures^b				
Hospitalization	686/1,795 (38.2)	426/1,248 (34.1)	260/547 (47.5)	<.0001

Variable	Overall (N = 1,801), No. (%) ^a	NAAT+/Toxin- (n = 1,252), No. (%) ^a	NAAT+/Toxin+ (n = 549), No. (%) ^a	P Value
LTACH stay	10/1,799 (0.6)	4/1,250 (0.3)	6 (1.1)	.08
Long-term care facility stay	95/1,799 (5.3)	41/1,250 (3.3)	54 (9.8)	<.0001
Emergency room visit	498/1,796 (27.7)	345/1,248 (27.6)	153/548 (27.9)	.90
Observational unit stay	74/1,796 (4.1)	44/1,248 (3.5)	30/548 (5.5)	.06
Chronic hemodialysis	154/1,799 (8.6)	120/1,250 (9.6)	34 (6.2)	.02
Surgery	208/1,797 (11.6)	112/1,248 (9.0)	96 (17.5)	<.0001
Prior medication exposures^b				
Antibiotic	1,226/1,789 (68.5)	782/1,242 (63.0)	444/547 (81.2)	<.0001
Proton pump inhibitor	1,127/1,793 (62.9)	773/1,247 (62.0)	354/546 (64.8)	.25
Immunosuppressant	1,185/1,794 (66.1)	831/1,247 (66.6)	354/547 (64.7)	.43
Clinical course and outcome				
3 unformed stools for 1 day	858/1,675 (51.2)	577/1,156 (49.9)	281/519 (54.1)	.11
Hospital admission ^c	1,335/1,800 (74.2)	947/1,251 (75.7)	388 (70.7)	.02
ICU admission ^d	119/1,800 (6.6)	86/1,251 (6.9)	33 (6.0)	.50
WBC 15,000/ μ L	464/1,604 (28.9)	269/1,126 (23.9)	195/478 (40.8)	<.0001
Serum albumin < 2.5 g/dL	403/1,494 (27.0)	266/1,054 (25.2)	137/440 (31.1)	.02
Pseudomembranous colitis	20/104 (19.2)	12/84 (14.3)	8/20 (40.0)	.009
Toxic megacolon or ileus	55/979 (5.6)	37/678 (5.5)	18/301 (6.0)	.74
Colectomy	3/1,800 (0.2)	2/1,251 (0.2)	1/549 (0.2)	1.00
CDI-related complications ^e	162/1,002 (16.2)	113/695 (16.3)	49/307 (16.0)	.91
CDI recurrence ^f	189 (10.5)	98 (7.8)	91 (16.6)	<.0001

Note. EIP, Emerging Infections Program; NAAT, nucleic acid amplification test; IQR, interquartile range; LTACH, long-term acute-care hospital; ICU, intensive care unit; WBC, white blood cell; CDI, *Clostridioides difficile* infection.

^aData are presented as no. (%) unless otherwise specified. Any missing response to a variable is excluded from the denominator.

^bDuring the 12 weeks prior to CDI diagnosis.

^cHospitalized at the time of or within 6 d following CDI diagnosis.

^dAdmitted to the ICU on the day of or within 6 d following CDI diagnosis.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

CDI-related complications defined as toxic megacolon, ileus, colectomy, or ICU admission on the day of or within 6 d following CDI diagnosis.

CDI recurrence defined as a *C. difficile*-positive stool 2–8 weeks following the initial positive test.

Table 2.

Multivariable Models Assessing *Clostridioides difficile* Infection (CDI)– Related Complications and Recurrence Between NAAT+/toxin– and NAAT+/toxin+ CDI Cases

Outcome	NAAT+/Toxin– vs NAAT+/Toxin+ CDI Cases	
	Adjusted Odds Ratio (95% CI)	P Value
CDI-related complications ^a	1.05 (0.87–1.28)	.60
CDI recurrence ^b	0.65 (0.55–0.77)	<.0001

Note. NAAT, nucleic acid amplification test; CDI, *Clostridioides difficile* infection; CI, confidence interval.

^aCDI-related complications defined as toxic megacolon, ileus, colectomy, or intensive-care unit admission on the day of or within 6 d following CDI diagnosis.

^bCDI recurrence defined as a *C. difficile*-positive stool 2–8 weeks following the initial positive test.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 3. Comparison of Treatment for *Clostridioides difficile* Infection (CDI) Between NAAAT+/Toxin- and NAAAT+/Toxin+ CDI Cases

Variable	Overall ^a	NAAAT+/Toxin- ^a	NAAAT+/Toxin+ ^a	P Value
All cases ^b	N=1,744	n=1,212	n=532	
Received CDI treatment	1376 (78.9)	866 (71.5)	510 (95.9)	<.0001
Any oral or rectal vancomycin	1,230/1,376 (89.4)	774/866 (89.4)	456/510 (89.4)	.98
Any fidaxomicin	59/1,376 (4.3)	23/866 (2.7)	36/510 (7.1)	<.0001
Metronidazole only	129/1,376 (9.4)	85/866 (9.8)	44/510 (8.6)	.47
FMT	11/1,376 (0.8)	7/866 (0.8)	4/510 (0.8)	1.00
Hospital-onset cases ^c	N=93	n=57	n=36	
Received CDI treatment	74 (79.6)	40 (70.2)	34 (94.4)	.007
Any oral or rectal vancomycin	70/74 (94.6)	38/40 (95.0)	32/34 (94.1)	1.00
Any fidaxomicin	5/74 (6.8)	0/40 (0)	5/34 (14.7)	.02
Metronidazole only	3/74 (4.1)	2/40 (5.0)	1/34 (2.9)	1.00
FMT	0/74 (0)	0/40 (0)	0/34 (0)	...
Non-hospital onset cases ^{d,e}	N=1651	n=1155	n=496	
Received CDI treatment	1,302 (78.9)	826 (71.5)	476 (96.0)	<.0001
Any oral or rectal vancomycin	1,160/1,302 (89.1)	736/826 (89.1)	424/476 (89.1)	.99
Any fidaxomicin	54/1,302 (4.2)	23/826 (2.8)	31/476 (6.5)	.001
Metronidazole only	126/1,302 (9.7)	83/826 (10.1)	43/476 (9.0)	.55
FMT	11/1,302 (0.8)	7/826 (0.9)	4/476 (0.8)	1.00

Note: NAAAT, nucleic acid amplification test; FMT, fecal microbiota transplantation.

^aData are presented as no. (%). Any missing response to a variable is excluded from the denominator.

^bExcludes 57 cases (40 NAAAT+/toxin- cases and 17 NAAAT+/toxin+ cases) with missing CDI treatment data or unknown duration of CDI treatment.

^cExcludes 2 cases (1 NAAAT+/toxin- case and 1 NAAAT+/toxin+ case) with missing CDI treatment data or unknown duration of CDI treatment.

^dExcludes 55 cases (39 NAAAT+/toxin- cases and 16 NAAAT+/toxin+ cases) with missing CDI treatment data or unknown duration of CDI treatment.

^eNon-hospital-onset cases include community-associated CDI cases, community-onset healthcare facility-associated CDI cases, and long-term care facility-onset CDI cases.

Table 4. Characteristics of NAAT+/Toxin- Cases by *Clostridioides difficile* infection Treatment Status^a

Variable	Treated for CDI (N = 866), No. (%) ^b	Not treated for CDI (N = 346), No. (%) ^b	P Value
Demographic			
Sex, female	501 (57.9)	186 (53.8)	.19
Race/ethnicity			
Hispanic, any race	48 (5.5)	26 (7.5)	.02
Non-Hispanic, White race	436 (50.4)	154 (44.5)	
Non-Hispanic, other race	239 (27.6)	121 (35.0)	
Unknown	143 (16.5)	45 (13.0)	
Age, median y (IQR)	62 (47–73)	57.5 (37–70)	.0001
Select medical conditions			
Chronic liver disease	42/864 (4.9)	29 (8.4)	.02
Chronic kidney disease	223/864 (25.8)	84 (24.3)	.58
Diabetes mellitus	269/864 (31.1)	107 (30.9)	.94
Diverticular disease	94/864 (10.9)	33 (9.5)	.49
Hematologic or solid-tumor malignancy	148/864 (17.1)	55 (15.9)	.60
Hematopoietic stem-cell or solid-organ transplant	37/864 (4.3)	16 (4.6)	.79
Inflammatory bowel disease	72/864 (8.3)	36 (10.4)	.25
History of CDI in prior 6 mo	41 (4.7)	29 (8.4)	.01
Prior healthcare exposures^c			
Hospitalization	285 (32.9)	130/344 (37.8)	.11
Long-term acute-care hospital stay	4 (0.5)	0/345 (0)	.58
Long-term care facility stay	31 (3.6)	9/345 (2.6)	.39
Emergency room visit	243 (28.1)	96/344 (27.9)	.96
Observational unit stay	28 (3.2)	16/344 (4.7)	.23
Chronic hemodialysis	81 (9.4)	38/345 (11.0)	.38
Surgery	73 (8.4)	36 (10.5)	.26
Prior medication exposures^c			

Variable	Treated for CDI (N = 866), No. (%) ^b	Not treated for CDI (N = 346), No. (%) ^b	P Value
Antibiotic	543/862 (63.0)	217 (62.7)	.93
Proton pump inhibitor	322 (37.2)	140 (40.5)	.29
Immunosuppressant	276 (31.9)	128 (37.0)	.09
Clinical course and outcome			
3 unformed stools for 1 d	443/825 (53.7)	126/297 (42.4)	.0009
Hospital admission ^d	658/865 (76.1)	275 (79.5)	.20
ICU admission ^e	62 (7.2)	22 (6.4)	.62
WBC 15,000/ μ L	205/796 (25.8)	59/310 (19.0)	.02
Serum albumin 2.5 g/dL	178/742 (24.0)	83/292 (28.4)	.14
Pseudomembranous colitis	9/53 (17.0)	2/29 (6.9)	.31
Toxic megacolon or ileus	29/502 (5.8)	8/166 (4.8)	.64
Colectomy	2/865 (0.2)	0 (0)	1.00
CDI-related complications ^f	83/513 (16.2)	28/172 (16.3)	.98
CDI recurrence ^g	70 (8.1)	27 (7.8)	.87

Note. NAAT, nucleic acid amplification test; IQR, interquartile range; CDI, *Clostridioides difficile* infection; ICU, intensive care unit; WBC, white blood cell.

^aExcludes 40 NAAT+/toxin- cases with missing CDI treatment data or unknown duration of CDI treatment.

^bData are presented as no. (%) unless otherwise specified. Any missing response to a variable is excluded from the denominator.

^cDuring the 12 weeks prior to CDI diagnosis.

^dHospitalized at the time of or within 6 d following CDI diagnosis.

^eAdmitted to the ICU on the day of or within 6 d following CDI diagnosis.

^fCDI-related complications defined as toxic megacolon, ileus, colectomy, or ICU admission on the day of or within 6 days following CDI diagnosis.

^gCDI recurrence defined as a *C. difficile*-positive stool 2–8 weeks following the initial positive test.

Table 5.

Final Multivariable Model to Identify Factors Associated with Treatment for *Clostridioides difficile* Infection Among NAAT+/Toxin- Cases

Variables	Adjusted Odds Ratio (95% CI)	P Value
Race/ethnicity		
Hispanic, Any race	0.86 (0.48–1.56)	.62
Non-Hispanic, White race	Referent	
Non-Hispanic, Other race	0.67 (0.47–0.94)	.02
History of CDI in prior 6 mo	0.47 (0.26–0.87)	.02
Long-term care facility stay in prior 12 weeks	2.65 (0.97–7.22)	.06
Diagnosis by a laboratory that provided no or neutral comments	3.23 (2.23–4.68)	<.0001
3 unformed stools for 1 d	1.90 (1.40–2.59)	<.0001
Hospital admission ^a	0.54 (0.35–0.86)	.009
WBC 15,000/ μ L	1.87 (1.28–2.74)	.001

Note. NAAT, nucleic acid amplification test; CDI, *Clostridioides difficile* infection; WBC, white blood cell.

^aHospitalized at the time of or within 6 d following CDI diagnosis.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript